Dr. Jacques Brown graduated from medical school and completed his residency in Internal Medicine at Laval University. He finished his residency in rheumatology at Université de Sherbrooke before undertaking post-doctoral training in metabolic bone diseases at the INSERM unit in Lyon, France.
He is a clinical researcher at the Centre de recherche du CHU de Québec-Laval University and a clinical professor at the Department of Medicine at Laval University. His major research interest is metabolic bone disorders such as Paget’s disease of bone, and osteoporosis.
Through the characterization of three French-Canadian families with Paget’s disease of bone, he first contributed to the discovery (2001) of the SQSTM1 gene mutations linked to this disease. In collaboration with Dr. Laëtitia Michou, this cohort now contains 43 families, 263 unrelated individuals with Paget’s disease and 298 controls, totalling 1,426 DNA samples with detailed phenotypes. The recruitment of new families and unrelated patients continues to help better identify new genetic factors of Paget’s disease of bone.
Since 1994, he has been a co-principal investigator and Quebec Centre Director on the Canadian Multicentre Osteoporosis Study (CaMOS), an epidemiologic study looking at the prevalence of osteoporosis, as well as the incidence of osteoporotic fractures in a large cohort (9,400 subjects) of the Canadian population. He is the principal investigator of the Recognizing Osteoporosis and its Consequences Programme, a patient health-management programme aimed at evaluating the diagnostic and treatment care gaps for osteoporosis following a fragility fracture in women 50 years of age and over.
He has published over 240 scientific articles in several high-impact journals. He has received several distinctions, including two John G. Haddad Jr. Research Awards from the Paget’s Foundation (2003 and 2005) and the Lindy-Fraser Memorial Award from Osteoporosis Canada (2004) for his work on the clinical practice guidelines of osteoporosis. In 2009, he was knighted to the Ordre National du Québec. More recently, Dr. Brown received the 2017 Distinguished Investigator Award from the Canadian Rheumatology Association for his exceptional contribution to rheumatology in Canada, and the Council of Physicians, Pharmacists, and Dentists of the CHU de Québec has awarded him the Diamant Hommage Héritage for the development and accomplishment of his career which will leave a solid legacy for the future of the institution.
2705, boulevard Laurier
Canada G1V 4G2
Data not available
Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.Journal Article
J Bone Miner Res, 2019, ISSN: 0884-0431.
Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.Journal Article
Osteoporos Int, 2019, ISSN: 0937-941X.
Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment.Journal Article
J Bone Miner Res, 34 (6), pp. 1033-1040, 2019, ISSN: 0884-0431.
Gene-environment interactions in Paget's disease of bone.Journal Article
Joint Bone Spine, 86 (3), pp. 373-380, 2019, ISSN: 1297-319X.
Parity and lactation are not associated with incident fragility fractures or radiographic vertebral fractures over 16 years of follow-up: Canadian Multicentre Osteoporosis Study (CaMos).Journal Article
Arch Osteoporos, 14 (1), pp. 49, 2019.
Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression.Journal Article
Osteoporos Int, 30 (4), pp. 721-740, 2019, ISSN: 0937-941X.
Number, Location, and Time Since Prior Fracture as Predictors of Future Fracture in the Elderly From the General Population.Journal Article
J Bone Miner Res, 33 (11), pp. 1956-1966, 2018, ISSN: 0884-0431.
Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.Journal Article
Arch Osteoporos, 13 (1), pp. 85, 2018.
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.Journal Article
J Bone Miner Res, 33 (8), pp. 1397-1406, 2018, ISSN: 0884-0431.
Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.Journal Article
J Clin Endocrinol Metab, 103 (7), pp. 2498-2509, 2018, ISSN: 0021-972X.
- Centres hospitaliers universitaires de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
Recently finished projects
- Clinical and molecular heterogeneity of Paget's disease of bone., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2013-10-01 to 2018-09-30
- Clinical validity and clinical utility of a screening test for Paget's disease of bone, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-03-01 to 2019-03-31